Advantages of Hubei Cangsheng Trading Co., Ltd.

1. High-Purity Products, Uncompromised Quality

Leveraging cutting-edge purification technologies and stringent quality control systems, our core products achieve purity levels exceeding 99.99%, precisely meeting the demands of high-tech industries such as electronics, pharmaceuticals, and new energy. Intelligent monitoring ensures batch-to-batch consistency, backed by ISO 9001-certified processesthat align with global quality benchmarks.  

2. China-Based Manufacturing, Integrated Supply Chain

As a proudly Chinese-manufactured brand, we harness domestic high-quality raw material suppliers and a mature industrial ecosystem to deliver cost efficiencyand agile production scalability. Fully automated production lines enable an annual capacity of metric tons, supporting large-scale orders while offering tailored R&D solutions for niche applications.  

3. Rapid Global Delivery Network

Our strategically located facilities and partnerships with top-tier logistics providers ensure fast-tracked shippingto clients worldwide. Real-time tracking and optimized routes reduce standard delivery cycles by over 30%, minimizing downtime for time-sensitive industries.  

4. Operational Excellence & Sustainability

AI-driven process optimization and lean management protocols maximize energy efficiencyand reduce waste. With a >95% on-time delivery rateand a carbon-neutral roadmap, we combine speed, reliability, and eco-conscious practices to drive value for global partners.  

Why Choose Us?

? Precision purityfor mission-critical applications  

? Cost-competitiveChina manufacturing edge  

? Faster turnaroundwithout compromising quality  

? End-to-end innovationfrom lab to logistics  

Perfectly engineered for tomorrow’s challenges.  

Description:

GW0742 is a high affinity PPAR-β/δ agonist reduces lung inflammation induced by bleomycin instillation in mice.

A high throughput screening campaign was conducted to identify small molecules with the ability to inhibit the interaction between the vitamin D receptor (VDR) and steroid receptor coactivator 2. These inhibitors represent novel molecular probes to modulate gene regulation mediated by VDR. The peroxisome proliferator-activated receptor δ (PPARδ) agonist GW0742 was among the identified VDR-coactivator inhibitors and has been characterized herein as a pan nuclear receptor antagonist at concentrations higher than 12.1 µM. The highest antagonist activity for GW0742 was found for VDR and the androgen receptor (AR). Surprisingly, GW0742 behaved as PPAR agonist/antagonist activating transcription at lower concentration and inhibiting this effect at higher concentrations. A unique spectroscopic property of GW0742 was identified as well. In the presence of rhodamine-derived molecules, GW0742+ increased fluorescence intensity and fluorescence polarization at an excitation wavelength of 595 nm and emission wavelength of 615 nm in a dose dependent manner. The GW0742-inhibited NR-coactivator binding resulted in a reduced expression of five different NR target genes in LNCaP cells in the presence of agonist. Especially VDR target genes CYP24A1, IGFBP-3 and TRPV6 were negatively regulated by GW0742. GW0742 is the first VDR ligand inhibitor lacking the secosteroid structure of VDR ligand antagonists. Nevertheless, the VDR-meditated downstream process of cell differentiation was antagonized by GW0742 in HL-60 cells that were pretreated with the endogenous VDR agonist 1,25-dihydroxyvitamin D3.